Literature DB >> 23194815

Comparison of psychophysical, electrophysiological, and fMRI assessment of visual contrast responses in patients with schizophrenia.

Daniel J Calderone1, Antígona Martinez, Vance Zemon, Matthew J Hoptman, George Hu, Jade E Watkins, Daniel C Javitt, Pamela D Butler.   

Abstract

Perception has been identified by the NIMH-sponsored Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) group as a useful domain for assessing cognitive deficits in patients with schizophrenia. Specific measures of contrast gain derived from recordings of steady-state visual evoked potentials (ssVEP) have demonstrated neural deficits within the visual pathways of patients with schizophrenia. Psychophysical measures of contrast sensitivity have also shown functional loss in these patients. In the current study, functional magnetic resonance imaging (fMRI) was used in conjunction with ssVEP and contrast sensitivity testing to elucidate the neural underpinnings of these deficits. During fMRI scanning, participants viewed 1) the same low and higher spatial frequency stimuli used in the psychophysical contrast sensitivity task, at both individual detection threshold contrast and at a high contrast; and 2) the same stimuli used in the ssVEP paradigm, which were designed to be biased toward either the magnocellular or parvocellular visual pathway. Patients showed significant impairment in contrast sensitivity at both spatial frequencies in the psychophysical task, but showed reduced occipital activation volume for low, but not higher, spatial frequency at the low and high contrasts tested in the magnet. As expected, patients exhibited selective deficits under the magnocellular-biased ssVEP condition. However, occipital lobe fMRI responses demonstrated the same general pattern for magnocellular- and parvocellular-biased stimuli across groups. These results indicate dissociation between the fMRI measures and the psychophysical/ssVEP measures. These latter measures appear to have greater value for the functional assessment of the contrast deficits explored here.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23194815      PMCID: PMC3544989          DOI: 10.1016/j.neuroimage.2012.11.019

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  63 in total

1.  Contrast in complex images.

Authors:  E Peli
Journal:  J Opt Soc Am A       Date:  1990-10       Impact factor: 2.129

2.  Magnocellular contributions to impaired motion processing in schizophrenia.

Authors:  Dongsoo Kim; Glenn Wylie; Roey Pasternak; Pamela D Butler; Daniel C Javitt
Journal:  Schizophr Res       Date:  2005-12-01       Impact factor: 4.939

3.  Spatiotemporal visual processing in schizophrenia.

Authors:  Szabolcs Kéri; Andrea Antal; György Szekeres; György Benedek; Zoltán Janka
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

4.  Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments.

Authors:  Pamela D Butler; Antigona Martinez; John J Foxe; Dongsoo Kim; Vance Zemon; Gail Silipo; Jeannette Mahoney; Marina Shpaner; Maria Jalbrzikowski; Daniel C Javitt
Journal:  Brain       Date:  2006-09-19       Impact factor: 13.501

5.  An electrophysiological technique for assessment of the development of spatial vision.

Authors:  V Zemon; E E Hartmann; J Gordon; A Prünte-Glowazki
Journal:  Optom Vis Sci       Date:  1997-09       Impact factor: 1.973

6.  Early sensory contributions to contextual encoding deficits in schizophrenia.

Authors:  Elisa C Dias; Pamela D Butler; Matthew J Hoptman; Daniel C Javitt
Journal:  Arch Gen Psychiatry       Date:  2011-03-07

7.  Effects of typical, atypical, and no antipsychotic drugs on visual contrast detection in schizophrenia.

Authors:  Yue Chen; Deborah L Levy; Summer Sheremata; Ken Nakayama; Steven Matthysse; Philip S Holzman
Journal:  Am J Psychiatry       Date:  2003-10       Impact factor: 18.112

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Sensory contributions to impaired emotion processing in schizophrenia.

Authors:  Pamela D Butler; Ilana Y Abeles; Nicole G Weiskopf; Arielle Tambini; Maria Jalbrzikowski; Michael E Legatt; Vance Zemon; James Loughead; Ruben C Gur; Daniel C Javitt
Journal:  Schizophr Bull       Date:  2009-09-30       Impact factor: 9.306

Review 10.  Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS.

Authors:  Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

View more
  23 in total

Review 1.  The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Authors:  M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2015-07-24       Impact factor: 4.530

2.  Functional MRI and EEG Index Complementary Attentional Modulations.

Authors:  Sirawaj Itthipuripat; Thomas C Sprague; John T Serences
Journal:  J Neurosci       Date:  2019-05-24       Impact factor: 6.167

3.  Altered Global Signal Topography in Schizophrenia.

Authors:  Genevieve J Yang; John D Murray; Matthew Glasser; Godfrey D Pearlson; John H Krystal; Charlie Schleifer; Grega Repovs; Alan Anticevic
Journal:  Cereb Cortex       Date:  2017-11-01       Impact factor: 5.357

4.  Schizophrenia Exhibits Bi-directional Brain-Wide Alterations in Cortico-Striato-Cerebellar Circuits.

Authors:  Jie Lisa Ji; Caroline Diehl; Charles Schleifer; Carol A Tamminga; Matcheri S Keshavan; John A Sweeney; Brett A Clementz; S Kristian Hill; Godfrey Pearlson; Genevieve Yang; Gina Creatura; John H Krystal; Grega Repovs; John Murray; Anderson Winkler; Alan Anticevic
Journal:  Cereb Cortex       Date:  2019-12-17       Impact factor: 5.357

5.  Sensory gain outperforms efficient readout mechanisms in predicting attention-related improvements in behavior.

Authors:  Sirawaj Itthipuripat; Edward F Ester; Sean Deering; John T Serences
Journal:  J Neurosci       Date:  2014-10-01       Impact factor: 6.167

Review 6.  Social Preference and Glutamatergic Dysfunction: Underappreciated Prerequisites for Social Dysfunction in Schizophrenia.

Authors:  Junghee Lee; Michael F Green
Journal:  Trends Neurosci       Date:  2016-07-29       Impact factor: 13.837

7.  What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia.

Authors:  Gaurav H Patel; Sophie C Arkin; Daniel R Ruiz-Betancourt; Heloise M DeBaun; Nicole E Strauss; Laura P Bartel; Jack Grinband; Antigona Martinez; Rebecca A Berman; David A Leopold; Daniel C Javitt
Journal:  Psychol Med       Date:  2020-06-05       Impact factor: 7.723

8.  Functional hierarchy underlies preferential connectivity disturbances in schizophrenia.

Authors:  Genevieve J Yang; John D Murray; Xiao-Jing Wang; David C Glahn; Godfrey D Pearlson; Grega Repovs; John H Krystal; Alan Anticevic
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

9.  Cognitive function mediates the relationship between visual contrast sensitivity and functional outcome in schizophrenia.

Authors:  Shaynna N Herrera; Vance Zemon; Nadine Revheim; Gail Silipo; James Gordon; Pamela D Butler
Journal:  J Psychiatr Res       Date:  2021-10-01       Impact factor: 4.791

10.  Visual Evoked Potential Abnormalities in Phelan-McDermid Syndrome.

Authors:  Paige M Siper; Mikaela A Rowe; Sylvia B Guillory; Audrey A Rouhandeh; Julia L George-Jones; Teresa Tavassoli; Stacey Lurie; Jessica Zweifach; Jordana Weissman; Jennifer Foss-Feig; Danielle Halpern; M Pilar Trelles; Maureen S Mulhern; Chloe Brittenham; James Gordon; Vance Zemon; Joseph D Buxbaum; Alexander Kolevzon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2021-07-22       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.